Appointment of non-executive board member

Dublin - May 17, 2017 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that in accordance with the explanatory notes to agenda item no. 7 of the next Annual General Meeting (AGM) to be held on 24 May 2017, the shareholders and the board of directors of COSMO Pharmaceuticals N.V. ("COSMO") have been provided with the opportunity to recommend a candidate for the position of non-executive board member. After careful consideration, the board of directors recommends Mrs. Eimear Cowhey to be appointed as non-executive board member at the AGM on 24 May 2017. The board of directors has conducted an extensive search and believes Mrs. Cowhey has notable experience to bring significant additional skills to the Board.

It is proposed to appoint Mrs. Eimear Cowhey as non-executive board member for a period of one year as of the date of the AGM. An overview of her credentials is available of the website of COSMO and is also available for inspection at the headquarters of COSMO, see http://www.cosmopharma.com/investor-relations/agm-2017.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company has developed a medical device for polyp and adenoma excision and is has completed clinical trials of LuMeBlue™, a diagnostic drug for the detection of colon cancer as well as new chemical entities that are being developed by the associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo's MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment®. Cosmo's proprietary MMX® technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company's website: www.cosmopharma.com